• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺微小乳头状癌等位基因频率与侵袭性行为之间的关联

Association Between Allele Frequency and Aggressive Behavior in Papillary Thyroid Microcarcinoma.

作者信息

Tatar Luiza, Bandargal Saruchi, Pusztaszeri Marc P, Forest Véronique-Isabelle, Hier Michael P, Kouz Jasmine, Chowdhury Raisa, Payne Richard J

机构信息

Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 0G4, Canada.

Department of Pathology, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.

出版信息

Cancers (Basel). 2025 Aug 1;17(15):2553. doi: 10.3390/cancers17152553.

DOI:10.3390/cancers17152553
PMID:40805249
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12346071/
Abstract

: Papillary thyroid microcarcinoma (MPTC), a subset of papillary thyroid carcinoma (PTC), is increasingly detected with advanced imaging. While most MPTCs are indolent, some exhibit aggressive behavior, complicating clinical management. The mutation, common in PTC, is linked to aggressive features, and its allele frequency (AF) may serve as a biomarker for tumor aggressiveness. This study explored the association between AF and aggressive histopathological features in MPTC. : Data from 1 January 2016 to 23 December 2023 were retrieved from two McGill University teaching hospitals. Inclusion criteria comprised patients aged ≥ 18 years with thyroid nodules ≤ 1 cm, documented mutation and AF results, and available surgical pathology reports. Tumor aggressiveness was defined as the presence of lymph node metastasis, aggressive histological subtype (tall cell, hobnail, columnar, solid/trabecular or diffuse sclerosing), extra thyroidal extension, or extensive lymphovascular extension. Associations were explored using -tests. : Among 1564 records, 34 met the inclusion criteria and were included in analyses. The mean AF was significantly higher in aggressive tumors (23.58) compared to non-aggressive tumors (13.73) (95% CI: -18.53 to -1.16, = 0.03). Although not statistically significant, trends were observed for higher AF in tumors with lymph node metastasis (mean AF: 25.4) compared to those without (mean AF: 16.67, = 0.08). No significant difference was noted in AF by histological subtype (mean AF for aggressive: 19.57; non-aggressive: 19.15, = 0.94). : Elevated AF is associated with aggressive behavior in MPTC, highlighting its potential as a biomarker to inform treatment strategies. Larger studies are warranted to validate these findings and enhance clinical management of MPTC patients.

摘要

甲状腺微小乳头状癌(MPTC)是甲状腺乳头状癌(PTC)的一个亚型,随着先进成像技术的应用,其检出率日益增加。虽然大多数MPTC生长缓慢,但有些表现出侵袭性行为,这使临床管理变得复杂。BRAF突变在PTC中很常见,与侵袭性特征相关,其等位基因频率(AF)可作为肿瘤侵袭性的生物标志物。本研究探讨了MPTC中BRAF AF与侵袭性组织病理学特征之间的关联。:从麦吉尔大学的两家教学医院检索了2016年1月1日至2023年12月23日的数据。纳入标准包括年龄≥18岁、甲状腺结节≤1 cm、有BRAF突变和AF结果记录以及有可用手术病理报告的患者。肿瘤侵袭性定义为存在淋巴结转移、侵袭性组织学亚型(高细胞型、鞋钉型、柱状型、实性/小梁型或弥漫性硬化型)、甲状腺外侵犯或广泛的淋巴管侵犯。使用t检验探索关联。:在1564条记录中,34条符合纳入标准并纳入分析。与非侵袭性肿瘤(13.73)相比,侵袭性肿瘤的平均BRAF AF显著更高(23.58)(95%CI:-18.53至-1.16,P = 0.03)。虽然无统计学意义,但观察到有淋巴结转移的肿瘤(平均AF:25.4)与无淋巴结转移的肿瘤(平均AF:16.67,P = 0.08)相比,BRAF AF有升高趋势。BRAF AF在不同组织学亚型之间无显著差异(侵袭性亚型平均AF:19.57;非侵袭性亚型:19.15,P = 0.94)。:BRAF AF升高与MPTC的侵袭性行为相关,突出了其作为指导治疗策略的生物标志物的潜力。需要更大规模的研究来验证这些发现并加强MPTC患者的临床管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af26/12346071/21bf51f27479/cancers-17-02553-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af26/12346071/3e139cc5b457/cancers-17-02553-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af26/12346071/3ca389329e18/cancers-17-02553-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af26/12346071/21bf51f27479/cancers-17-02553-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af26/12346071/3e139cc5b457/cancers-17-02553-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af26/12346071/3ca389329e18/cancers-17-02553-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af26/12346071/21bf51f27479/cancers-17-02553-g003.jpg

相似文献

1
Association Between Allele Frequency and Aggressive Behavior in Papillary Thyroid Microcarcinoma.甲状腺微小乳头状癌等位基因频率与侵袭性行为之间的关联
Cancers (Basel). 2025 Aug 1;17(15):2553. doi: 10.3390/cancers17152553.
2
Association of BRAF V600E allele frequency with clinicopathologic outcomes in papillary thyroid cancer.BRAF V600E等位基因频率与甲状腺乳头状癌临床病理结果的相关性
J Clin Endocrinol Metab. 2024 Nov 14. doi: 10.1210/clinem/dgae774.
3
Genetic alterations and allele frequency of BRAF V600E and TERT mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study.具有中高危复发风险的甲状腺乳头状癌中 BRAF V600E 和 TERT 突变的基因改变和等位基因频率:一项回顾性研究。
Clin Exp Med. 2024 Apr 12;24(1):76. doi: 10.1007/s10238-024-01320-4.
4
Multigene Detection Analysis of Multifocal Papillary Thyroid Carcinoma.多灶性甲状腺乳头状癌的多基因检测分析
Clin Endocrinol (Oxf). 2025 Aug;103(2):251-259. doi: 10.1111/cen.15251. Epub 2025 Apr 15.
5
Distinctive hobnail subtype of papillary thyroid carcinoma: a case series and short review of literature.甲状腺乳头状癌独特的鞋钉样亚型:病例系列及文献综述
Hormones (Athens). 2025 Jun 25. doi: 10.1007/s42000-025-00692-w.
6
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.甲状腺乳头状癌中的BRAF突变及其在制定初始治疗方案中的价值:一项系统评价和荟萃分析。
Medicine (Baltimore). 2012 Sep;91(5):274-286. doi: 10.1097/MD.0b013e31826a9c71.
7
Risk and Prognostic Factors for BRAF Mutations in Papillary Thyroid Carcinoma.甲状腺乳头状癌中 BRAF 突变的风险和预后因素。
Biomed Res Int. 2022 May 18;2022:9959649. doi: 10.1155/2022/9959649. eCollection 2022.
8
The Association between Lymphocytic Thyroiditis and Papillary Thyroid Cancer Harboring Mutant : A Systematic Review and Meta-Analysis.淋巴细胞性甲状腺炎与携带突变的甲状腺乳头状癌之间的关联:一项系统评价和荟萃分析。
Thyroid. 2024 Sep;34(9):1082-1093. doi: 10.1089/thy.2024.0142. Epub 2024 Jul 18.
9
THE RELATIONSHIP OF BRAF MUTATION STATUS TO FDG PET/CT AVIDITY IN THYROID CANCER: A REVIEW AND META-ANALYSIS.甲状腺癌中 BRAF 突变状态与 FDG PET/CT 摄取的关系:综述和荟萃分析。
Endocr Pract. 2018 Jan;24(1):21-26. doi: 10.4158/EP-2017-0080. Epub 2017 Nov 16.
10
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险

本文引用的文献

1
Association of BRAF V600E allele frequency with clinicopathologic outcomes in papillary thyroid cancer.BRAF V600E等位基因频率与甲状腺乳头状癌临床病理结果的相关性
J Clin Endocrinol Metab. 2024 Nov 14. doi: 10.1210/clinem/dgae774.
2
Genetic alterations and allele frequency of BRAF V600E and TERT mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study.具有中高危复发风险的甲状腺乳头状癌中 BRAF V600E 和 TERT 突变的基因改变和等位基因频率:一项回顾性研究。
Clin Exp Med. 2024 Apr 12;24(1):76. doi: 10.1007/s10238-024-01320-4.
3
Clinical and molecular features of progressive papillary thyroid microcarcinoma.
进展性甲状腺微小乳头状癌的临床和分子特征。
Int J Surg. 2024 Apr 1;110(4):2313-2322. doi: 10.1097/JS9.0000000000001117.
4
Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers.跨癌症的BRAF原癌基因/丝裂原活化蛋白激酶(MAPK)通路的分子靶向治疗
Int J Mol Sci. 2024 Jan 3;25(1):624. doi: 10.3390/ijms25010624.
5
The Impact of Mutation Allele Frequency on the Histopathological Characteristics of Thyroid Cancer.突变等位基因频率对甲状腺癌组织病理学特征的影响
Cancers (Basel). 2023 Dec 25;16(1):113. doi: 10.3390/cancers16010113.
6
BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.BRAF V600E 突变与致癌突变共存与甲状腺乳头状癌侵袭性临床病理特征和不良预后相关。
Asian J Surg. 2024 Jan;47(1):413-419. doi: 10.1016/j.asjsur.2023.09.049. Epub 2023 Sep 24.
7
Impact of V600E Mutation on Event-Free Survival in Patients with Papillary Thyroid Carcinoma: A Retrospective Study in a Romanian Population.V600E突变对甲状腺乳头状癌患者无事件生存期的影响:罗马尼亚人群的回顾性研究
Cancers (Basel). 2023 Aug 11;15(16):4053. doi: 10.3390/cancers15164053.
8
Younger Than 55 Years Old and V600E Mutation are Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinomas ≤1.0 cm but Not in >1.0 cm.年龄小于55岁和V600E突变是直径≤1.0 cm的乳头状甲状腺癌发生淋巴结转移的危险因素,但在直径>1.0 cm的乳头状甲状腺癌中并非如此。
Int J Gen Med. 2023 Apr 19;16:1403-1414. doi: 10.2147/IJGM.S408588. eCollection 2023.
9
Association of BRAF Mutation with the Aggressive Behavior of Papillary Thyroid Microcarcinoma: A Meta-Analysis of 33 Studies.BRAF 突变与甲状腺微小乳头状癌侵袭性行为的相关性:33 项研究的荟萃分析。
Int J Mol Sci. 2022 Dec 9;23(24):15626. doi: 10.3390/ijms232415626.
10
Hobnail Papillary Thyroid Carcinoma, A Systematic Review and Meta-Analysis.甲状腺乳头状癌,一项系统评价与荟萃分析
Cancers (Basel). 2022 Jun 3;14(11):2785. doi: 10.3390/cancers14112785.